Doç.Dr. Türkan Öztürk Topcu

Tıbbi Onkoloji

Eğitim
  • 1998-2004: Lisans,  Cumhuriyet Üniversitesi Tıp Fakültesi
  • 2005-2010: İç Hastalıkları Uzmanlık, İstanbul Haydarpaşa Numune Eğitim ve Araştırma Hastanesi
  • 2011-2015: Tıbbi Onkoloji Uzmanlık, Karadeniz Teknik Üniversitesi Tıp Fakültesi
  • 2016-2018: Doçent , İstanbul Medeniyet Üniversitesi Göztepe Eğitim Araştırma Hastanesi

 

İş Deneyimi

  • 2005-2010: İstanbul Haydarpaşa Numune eğitim araştırma Hastanesi
  • 2008-2009: Klinik Gözlemci,  MD Anderson Kanser Merkezi (Amerika)
  • 2010 - 2011:Mecburi Hizmet, İdil Devlet Hastanesi, İç Hastalıkları Uzmanı
  • 2016-2018: İstanbul Medeniyet Üniversitesi Göztepe Eğitim Araştırma Hastanesi
  • 2017 :  Ziyaretçi Araştırmacı, Kanada Sunnybrook Hospital, Odette Cancer Center (Toronto) Meme ve Akciğer kanseri
Üyelikler
  • Türk Tıbbi Onkoloji Derneği
  • Avrupa Medikal Onkoloji Derneği, European Society for Medical Oncology (ESMO)
  • Amerika Medikal Onkoloji Derneği, American Society Of Medical Oncolog (ASCO)
Tıbbi İlgi Alanları
  • Solid Tümörler
Yabancı Diller
  • Solid Tümörler
Doğum Yeri / Tarihi
  • Niğde
Bilimsel Yayınlar
BİLİMSEL YAYINLAR

1.Ozturk Topcu T, Jerzak KJ, Warner E. RE: Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status. J Natl Cancer Inst. 2018 Jan 10. doi: 10.1093/jnci/djx290.

2.Topcu TO, Ozdemir F, Kavgaci H, Gunaldi M, Kocoglu H, Imamoglu GI, Mentese A, Yaman SO, Orem A, Aydin F. The clinical importance of serum urokinase plasminogen activator receptor and carbonic anhydrase IX levels and the effect of anthracycline-based adjuvant chemotherapy on these biomarkers in breast cancer. J Cancer Res Ther. 2018 Apr-Jun;14(3):608-613. doi: 10.4103/0973-1482.174547.

3. Inal A, Kodaz H, Odabas H, Duran AO, Seker MM, İnanc M, Elkıran ET, Gunaydın Y, Menekse S, Topcu TO, Urakcı Z, Tastekin D, Bilici M, Cihan S, Geredeli C, Sezer E, Uncu D, Arpacı E, Ozturk B, Bal O, Uysal M, Tanrıverdi O, Gumus M, Oven Ustaalioglu BB, Suner A, Cokmert S, Hacıbekiroglu İ, Aydın K, Isıkdogan A. Prognostic factors of patients who received chemotherapy after cranial irradiation for non-small cell lung cancer with brain metastases: A retrospective analysis of multicenter study (Anatolian Society of Medical Oncology). J Cancer Res Ther. 2018 Apr-Jun;14(3):578-582. doi: 10.4103/0973-1482.176417.

4. Gunaldi M, Isiksacan N, Kocoglu H, Okuturlar Y, Gunaldi O, Topcu TO, Karabulut M. The value of serum survivin level in early diagnosis of cancer. J Cancer Res Ther. 2018 Apr-Jun;14(3):570-573. doi: 10.4103/0973-1482.171369.

5. Aksu Arıca D, Ozturk Topcu T, Baykal Selçuk L, Yaylı S, Seyman U, Fidan E, Bahadır S, Kavgacı H. Assessment of demodex presence in acne-like rash associated with cetuximab. Cutan Ocul Toxicol. 2017 Sep;36(3):220-223. doi: 10.1080/15569527.2016.1253095. Epub 2016 Nov 16.

6. Topcu TO, Kavgaci H, Ozdemir F, Aksoy A, Erdem D, Mentese A, Yaman H, Tufan G, Orem A, Aydin F.(2015) Elevated Serum Levels of SCUBE1, a Marker for Coagulation, in Patients with Breast Cancer.
Tohoku J Exp Med. 2015 Oct;237(2):127-32.

7. Topcu TO, Kavgacı H, Canyılmaz E, Orem A, Yaman H, Us D, Ozdemir F, Aydın F.(2015)The effect of adjuvant chemotherapy on plasma TAT and F 1+2 levels in patients with breast cancer.Biomed Pharmacother. 2015 Jul;73:19-23

8.Topcu TO, HalilKavgaci, MeralGunaldi, HakanKocoglu, Murat Akyol, AhmetMentese, SerapOzerYaman, Asim Orem, FeyyazOzdemir, Fazil Aydin.(2017) The clinical importance of serum galectin-3 levels in breast cancer patients with and without metastasis. Journal of Cancer Research and Therapeutics.

9. Ercelep O, Topcu TO, Bayoglu IV, Ekinci AS, Koca S, Kavgaci H, Ozcelik M, Alacacioglu A, Uzunoglu S, Bozkurt O, Ulas A, Aksoy A, Taskoylu BY, Gumussay O, Yaman S, Uysal M, Aydin D, Gumus M. Retrospective multicenter evaluation of patients diagnosed with mucosal melanoma: a study of Anatolian Society of Medical Oncolog.Tumour Biol. 2016 Sep;37(9):12033-12038.

10. Aksu Arıca D, OzturkTopcu T, Baykal Selçuk L, Yaylı S, Seyman U, Fidan E, Bahadır S, Kavgacı H. Assessment of demodex presence in acne-like rash associated with cetuximab.CutanOculToxicol. 2016 Nov 16:1-4.

11. Gumus M, Bilici A, Odabas H, Ustaalioglu BB, Kandemir N, Demirci U, Cihan S, Bayoglu IV, Ozturk T, Turkmen E, Urakci Z, Seker MM, Gunaydin Y, Selcukbiricik F, Turan N, Sevinc A. Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors.World J Urol. 2016 Nov 3

12.Bilici A, Ozturk T, Turkmen E, Odabas H, Cihan S, Selcukbiricik F, Erdogan B, Urakci Z, Kandemir N, Bayoglu IV, Demirci U, Duran AO, Sendur MA, Yavuzer D, Harputluoglu H, Kavgaci H, Gumus M. Treatment preferences in stage IA and IB testicular seminoma: multicenter study of Anatolian Society of Medical Oncology.World J Urol. 2015 Oct;33(10):1613-22. doi: 10.1007/s00345-015-1492-9.

13.Aksoy A, Karaoglu A, Akpolat N, Naziroglu M, Ozturk T, Karagoz ZK. Protective Role of Selenium and High Dose Vitamin E against Cisplatin - Induced Nephrotoxicty in Rats. Asian Pac J Cancer Prev. 2015;16(16):6877-82.

14.Tanriverdi O, Kaytan-Saglam E, Ulger S, Bayoglu IV, Turker I, Ozturk-Topcu T, Cokmert S, Turhal S, Oktay E, Karabulut B, Kilic D, Kucukzeybek Y, Oksuzoglu B, Meydan N, Kaya V, Akman T, Ibis K, Saynak M, SenCA, Uysal-Sonmez O, Pilancı KN, Demir G, Saglam S, Kocar M, Menekse S, Goksel G, Yapar-Taskoylu B, Yaren A, Uyeturk U, Avci N, Denizli B, Ilis-Temiz E. The clinical and pathological features of 133 colorectal cancer patients with brain metastasis: a multicenter retrospective analysis of the Gastrointestinal Tumors Working Committee of the Turkish Oncology Group (TOG). Med Oncol. 2014 Sep;31(9):152. doi: 10.1007/s12032-014-0152-z. Epub 2014 Aug 10

15.Serdar Lasif,Canyilmaz Emine, Ozturk Topcu Turkan, Sahbaz Aslı,Memiş Yahyahan,Soydemir Gulşen, Aynacı Ozlem,Kandaz Mustafa Bahat Zumrut, Yoney Adnan (2015).Adjuvant radiotherapy in stage 1 seminoma: Evaluation of prognostic factors and resultsof survival. Journal of Cancer Research and Therapeutics, 11(2), 313, Doi: 10.4103/0973-1482.140846, (Kontrol No: 2634890)

16.Inal Ali, Kodaz Hilmi, Odabaş Hatice,Ocak duran Ayşe,Seker Metin, Inanc Mevlide, Elkıran Emin Taner,Gunaydın Yusuf, Menekşe Serkan, Ozturk Topcu Turkan, Urakcı Zuhat, Tastekin Didem, Bilici Mehmet, Caglayan Sener Cihan, Sezer Emel, Uncu Dogan, Arpaci Erkan, Ozturk Banu, Bal Oznur,Uysal Mukremin, Tanrıverdi Ozgur, Gumus Mahmut, Oven Basak, Suner Ali, Cokmert Suna, Hacibekiroglu Ilhan, Aydın Kubra, Isıkdogan Abdurrahman. Prognostic factors of patients who received chemotherapyafter cranial irradiation for non-small cell lung cancer with brain metastases: ARetrospective Analysis of multicenter study (Anatolian Society of Medical Oncology).Journal of Cancer Research and Therapeutics.

17.Berk Velı,Kaplan Mehmet Alı,Tonyalı Önder,Büyükberber Süleyman,Balakan Ozan,Özkan Metın,Demırcı Umut,Ozturk Turkan,Tastekın Dıdem,Bılıcı Ahmet,ÖzdemırNurıye,Ünal Olçun Ümıt,Oflazoglu Utku,Türkmen Esma,Erdogan Bülent,ÜyetürkÜmmügül,Çakmak Öksüzoglu Ömür Berna,Yesıl Çınkır Havva,Yasar Nurgül,Gümüs
Mahmut (2013). Efficiency and Side Effects of Sorafenib Therapy for AdvancedHepatocellular Carcinoma: A Retrospective Study by the Anatolian Society of MedicalOncology. Asian Pacific Journal of Cancer Prevention, 14(12), 7367-7369., Doi: 10.7314/APJCP.2013.14.12.7367, (Kontrol No: 2635489)

18.Günaldı Meral,Isıksaçan Nılgün,Koçoglu Hakan,Okuturlar Yıldız,Günaldı Ömür,Ozturk Topcu Turkan,Karabulut Mehmet. The value of serum survivin level in earlydiagnosis of cancer. Journal of Cancer Research and Therapeutics

19.Turan Nedım,Beneklı Mustafa,Ünal Olçun Ümıt,Ünek Ilkay Tugba,Tastekın Dıdem,DaneFaysal,Algın Efnan,Ülger Sükran,Eren Tülay,Ozturk Topcu Turkan,Türkmen Esma,Akgül Babacan Nalan,Tufan Gülnıhal,Urakcı Zuhat,Öven Ustaalıoglu Basak,SönmezUysal Özlem,Balvan Erçelep Özlem,Yapar Tasköylü Burcu,Aksoy Asude,CanhorozMustafa,Demırcı Umut,Dogan Erkan,Berk Velı,Balakan Ozan,Ekıncı Ahmet Sıyar,UysalMükremın,Petekkaya Ibrahım,Öztürk Selçuk Cemıl,Tonyalı Önder,Çetın Bülent,Aldemır Mehmet Nacı,Helvacı Kaan,Özdemır Nurıye,Öztop Ilhan,Coskun Ugur,ÜnerAytug,Özet Ahmet,Büyükberber Süleyman (2015). Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullaryadenocarcinoma. Chinese Journal of Cancer Research, (Kontrol No: 2636031)

20.Aksoy A, Odabas H, Kaya S, Bozkurt O, Degirmenci M, Topcu TO, Aytekin A, Arpaci E, Avci N, Pilanci KN, Cinkir HY, Bozkaya Y, Cirak Y, Gumus M. Hormone receptor status and survival of medullary breast cancer patients. A Turkish cohort.Saudi Med J. 2017 Feb;38(2):156-162. doi: 10.15537/smj.2017.2.18055.

21.Cicin İ, Özatlı T, Türkmen E, Ozturk T, Özçelik M, Çabuk D, Gökdurnalı A, Balvan Ö, Yıldız Y, Şeker M, Özdemir N, Yapar B, Tanrıverdi Ö, Günaydin Y, Menekşe S, Öksüzoğlu B, Aksoy A, Erdogan B, Bekir Hacıoglu M1, Arpaci E, Sevinç A. Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas. Balkan Med J. 2016 Sep;33(5):517-524. Epub 2016 Sep 1.

22.Cikrikcioglu MA, Hursitoglu M, Erkal H, Inan B, Ozturk T, Cakirca M, Canpolat F, Erkal S, Bahtiyar I, Cordan I, Tukek T.Splenomegaly in primary antiphospholipid syndrome without accompanying portal hypertension or comorbidity.Pathophysiol Haemost Thromb. 2010;37(2-4):104-9. doi: 10.1159/000327506. Epub 2011 May 10

Presented And/OrPublishedAbstracts

1. Ozturk Topcu Turkan,Özdemır Feyyaz,Kavgacı Halıl,Kocoglu Hakan,Imamoglu Inanc,Mentese Ahmet,Özer Yaman Serap,Örem Asım,Aydın Fazıl (2015). The Clinicalİmportance Of Serum Upar And Caıx Levels And The Effect On These Of AnthracyclinebasedAdjuvant Chemotherapy İn Breast Cancer. Mediterranean Multidisciplinary OncologyForum (Poster), (Kontrol No: 2640967)

2. Ozturk Topcu Turkan,Özdemır Feyyaz,Kavgacı Halıl,Mentese Ahmet,Özer YamanSerap,Örem Asım,Aydın Fazıl (2015). Plasma Malondialdehyde And Ischemia-ModifiedAlbumin Levels İn Breast Cancer Patients Before And After Adjuvant Chemotherapymediterranean Multidisciplinary Oncology Forum (Poster), (Kontrol No: 2640954)

3. Aydın Fazıl,Öztürk Topcu Turkan,Özdemır Feyyaz,Kavgacı Halıl,Sahın Nazım Onur,Kandaz Mustafa (2014). Pazopanib For The Treatment Of Metastatik Nonadipocytic SoftTissue Sarcoma. American Society Of Clinical Oncology (Poster), (Kontrol No: 2640751)

4. Ozturk Topcu Turkan,Kavgacı Halıl,Gunaldı Meral,Mentese Ahmet,Örem Asım,Özdemır Feyyaz,Aydın Fazıl (2015). The Clinical Importance Of Serum Galectin-3 Levelsİn Patients With Breast Cancer. Mediterranean Multidisciplinary Oncology Forum (Poster),(Kontrol No: 2640947)

5. Kocoglu Hakan,Gunaldı Meral,Ascı Emıne,Okuturlar Yıldız,Isıksacan Nılgun,OzturkTopcu Turkan,Tıken Elıf Eda (2015). Does Body Mass Index (Bmı) Influence Long TermSurvival In Gastric Cancer Patients?. 5th International Gastrointestinal Cancers Conference(Poster), (Kontrol No: 2640844)

6. Kaplan Muammet Alı,Urakcı Zuhat,Gümüs Mahmut,Ülkü Arslan,Geredelı Caglayan,Özdemır Nurıye,Koca Dogan,Oruc Zeynep,Uysal Mükremın,Dane Faysal,Sevınç Alper,Seker Mehmet Metın,Aksoy Asude,Küçüköner Mehmet,Pılancı Kezban,Öztürk Topcu Turkan,Karaagaç Mustafa,Yıldız Ramazan,Isıkdogan Abdurrahman (2015). What AreThe Differences Between Young (25 Years) And Adult (>25 Years) Colorektal Cancer(Crc) An Anatolian Society Of Medical Oncology Study. American Society Of Clinical Oncology(Poster), (Kontrol No: 2640918)

7. Erçelep Özlem,Ekıncı Ahmet Sıyar,Bayoglu Ibrahım Vedat,Uzunoglu Sernaz,UlasArıfe,Bozkurt Oktay,Aksoy Asude,Gumuscay Özge,Yaman Sebnem,Ozcelık Melıke,Ozturk Topcu Turkan,Yapar Burcu,Uysal Mükremın,Özdemır Nurıye,AlacacıogluAhmet,Çakmak Öksüzoglu Ömür Berna,Sevınç Alper,Gümüs Mahmut (2014). TreatmentAnd Prognosis İn Mukosal Melanoma: An Anatolian Society Of Medical Oncology. American
Society Of Clinical Oncology (Poster), (Kontrol No: 2640811)

8. Turan Nedım,Beneklı Mustafa,Ünal Orçun Ümıt,Ünek Ilkay Tugba,Tastekın Dıdem,Dane
Faysal,Algın Efnan,Ülger Sükran,Eren Tülay,Ozturk Topcu Turkan,Türkmen Esma,Babacan Nalan,Tufan Gülnıhal,Urakcı Zuhat,Ustaalıoglu Basak,Uysal Özlem,ErçelepÖzlem,Tasköylü Burcu,Aksoy Asude,Canhoroz Mustafa (2014). Impact Of AdjuvantTreatment Modalities On Survival Outcomes In Curatively Resected Pancreatic AndPeriampullary Adenocarcinoma. Europian Society Of Medical Oncology (Poster), (Kontrol No:2640740)

9. Gunaldı Meral,Isıksacan Nılgun,Kocoglu Hakan,Okuturlar Yıldız,Gunaldı Omur,Ozturk Topcu Turkan,Karabulut Mehmet (2016). Evaluation Of Serum Survivin Level AsA Risk Indikator And A Diagnosis Marker In Patients With Cancer.SanAntonio Breast CancerSymposium 2016 (Poster), (Kontrol No: 2640

10.Adachı Javıer,Saud Ahmed,Hachem Ray,Lasala Rocco,Ozturk Turkan,Vıgıl Karen (2009). Clinical Outcome Of Multidrug Resistant (Mdr) Pseudomonas Infections. Does Resistance To Colistin Predict Failure İn Cancer Patients?. Infectious Diseases Society Of America (Poster), (Kontrol No: 2755600)

11.Saud Ahmed,Ozturk Turkan,Khokhar Faısal,Mulanovıch Vıctor (2009). Toxoplasmosis (Txp) İn Hematological Malignancy (Hm) Patients (Pts) At MD Anderson Cancer Center(Mdacc). Infectious Diseases Society Of America (Poster), (Kontrol No: 2755515)


Sub-Investigator in Clinical Trials

1.Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer ( Monarch-E 13y-Mc-Jpcf)

2.A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer ( Impassion 131)

3.A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)

4.A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

5.First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)

6.Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma (IMvigor130)

7.A Phase 1b/2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (FIERCE 21)

8.Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC)

9.Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer

10.AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. (ADAURA)

11.International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study (BREAKOUT).